Find clinical trials for Leukemia in Rochester, MN
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Leukemia trials near Rochester, MN, USA:
in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has completed enrollment.In Sub-studies 1 and 2...
Phase 1, Phase 2
Rochester, Minnesota, United States and 55 other locations
allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia...
Phase 3
Rochester, Minnesota, United States and 23 other locations
Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib ...
Phase 2
Rochester, Minnesota, United States and 43 other locations
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia....
Phase 1
Rochester, Minnesota, United States and 22 other locations
This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN...
Phase 1, Phase 2
Rochester, Minnesota, United States and 28 other locations
of CTX-712 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (HR-MDS).The ph...
Phase 1, Phase 2
Rochester, Minnesota, United States and 3 other locations
The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine...
Phase 2
Rochester, Minnesota, United States and 9 other locations
with azacitidine to improve Overall Survival (OS) in Acute Myeloid Leukemia (AML) participants compared to Best Supportive Care (BSC) when g...
Phase 3
Rochester, Minnesota, United States and 164 other locations
participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). This study will also allow participants who are currently...
Phase 1
Rochester, Minnesota, United States and 21 other locations
designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic lymphocytic leukemia...
Phase 3
Rochester, Minnesota, United States and 130 other locations
Clinical trials
Research sites
Resources
Legal